X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
XOMA acquired an economic interest in DSUVIA® (sufentanil sublingual tablet), an opioid agonist, indicated for use in adults, for the management of acute pain, from Talphera.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: XOMA
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 18, 2024
Details:
Under the divestment, Alora will accelerate the commercialization of Dsuvia (sufentanil), a synthetic opioid analgesic formulation for the management of acute pain.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alora Pharmaceuticals
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Divestment April 05, 2023
Details:
The divestment allows AcelRx to participate in the long-term value expected to be created by Alora as they expand the commercialization of Dsuvia (sufentanil citrate).
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alora Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment March 14, 2023
Details:
DSUVIA (sufentanil), an opioid analgesic, is indicated for use in adults for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
DZUVEO® (sufentanil sublingual tablet, 30 mcg), a novel sublingual approach to acute pain management, was designed to provide rapid analgesia via a non-invasive route and to eliminate high peak plasma levels and provide longer duration of action.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dzuveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Dsuvia (sufentanil) is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia, is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
DSUVIA, known as DZUVEO (sufentanil citrate) in Europe, is indicated for use in adults in certified medically supervised healthcare settings, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
DSUVIA (sufentanil sublingual tablet), known as DZUVEO® in Europe, is indicated for use in adultsfor the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Study found that Dzuveo (Sufentanil Citrate) lowered the opioid dose required by patients in the post-anesthesia care unit (PACU) by more than five-fold compared to standard intravenous opioid administration.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dzuveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
DSUVIA (sufentanil sublingual tablet), known as DZUVEO in Europe, is indicated for use in adults in certified medically supervised healthcare settings for management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
DSUVIA, known as DZUVEO in Europe, is indicated for use in adults in certified medically supervised healthcare settings, for management of acute pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2021
Details:
Under the DZUVEO licensing agreement, Aguettant will have the right to commercialize DZUVEO in Europe. In 2018, AcelRx received approval for DZUVEO from the European Commission for use in medically monitored settings.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dzuveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aguettant
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 14, 2021
Details:
AcelRx has been awarded the contract by the U.S. Army for the purchase of DSUVIA to support a study to aid the development of clinical practice guidelines. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate IV associated dosing errors.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Army
Deal Size: $3.6 million Upfront Cash: Undisclosed
Deal Type: Agreement September 22, 2020
Details:
A recent study and preliminary data from other open-label studies using DSUVIA in the perioperative environment suggest a substantial decline in the amount of opioids used in the PACU, and a dramatic decrease in time to discharge from the PACU with DSUVIA-treated patients.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
